Charting new paths to superior medicines
Iambic’s cutting-edge AI-driven platform tackles the most challenging design problems in drug discovery, addressing unmet patient need.
Optimized medicines for optimized profiles
Our physics-based AI algorithms drive a high-throughput experimental platform, converting new molecular designs to new biological insights each week.
Exploring multiple profiles in parallel ensures that we design molecules to solve the right problems in disease biology
Our AI-driven platform deeply explores chemical space, revealing novel mechanisms of action and delivering diverse high-quality leads
Innovation
Accurate and data-efficient physics-based AI technologies that span from early-stage discovery to the clinic
Automation
AI-driven, high-throughput experimentation to go from new molecular designs to new biological data each week
Execution
A proprietary pipeline of differentiated clinical candidates delivered at a pace years faster than the industry standard
Platform-driven pipeline of first-in-class and best-in-class programs
We are unlocking the untapped potential of known targets and transforming seemingly undruggable targets into opportunities for breakthrough treatments.
1000x selectivity and brain penetrance to unlock the therapeutic potential of the target for metastatic disease with IND submission in 2023
First-in-class CDK2/4 profile to address cyclin D and cyclin E driven cancers while avoiding off-target dose-limiting toxicities
Programs focusing on cryptic pockets, allostery, and protein-protein interactions, spanning multiple therapeutic areas
Innovation through the collaboration of AI experts and drug hunters
By placing AI innovations in the hands of our seasoned drug hunters, we’re optimizing our path towards differentiated therapeutics.
.jpg)
News & Media
Read our recent announcements
Iambic Therapeutics Announces the Addition of Dr. Mary Tagliaferri to its Board of Directors
Iambic Therapeutics Announces the Addition of Dr. Mary Tagliaferri to its Board of Directors
Presentations
Stay tuned for upcoming talks from our team.
.jpg)
.jpg)
.jpg)